Back to top
more

Better trading starts here.

Brokerage Reports

Research for REGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Regeneron Pharmaceuticals, Inc. [REGN]

Reports for Purchase

Showing records 541 - 560 ( 593 total )

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 541

09/21/2012

Company Report

Pages: 4

Positive CHMP Opinion for Eylea in the E.U. for Wet AMD

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 542

09/21/2012

Company Report

Pages: 6

Eylea Approved in CRVO, as Anticipated; Raising PT to $162

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 543

09/20/2012

Daily Note

Pages: 9

MORNING CALL SUMMARY.

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 544

09/20/2012

Company Report

Pages: 4

Anticipating Eylea Approval in CRVO and Continued Revenue Growth

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 545

08/18/2012

Industry Report

Pages: 15

What Was Supposed to Be a Quiet Week Turns Into a Busy Week

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 50.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 546

08/10/2012

Company Report

Pages: 8

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 547

08/06/2012

Daily Note

Pages: 21

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 548

08/03/2012

Company Report

Pages: 4

ZALTRAP Approved; Important Headline, Financial Impact May Take A While

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 549

07/31/2012

Daily Note

Pages: 22

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 550

07/31/2012

Company Report

Pages: 4

Arcalyst Not Approved for Gout, as Expected; Projecting ZALTRAP Approval

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 551

07/28/2012

Industry Report

Pages: 21

BIOTECH BALANCE SHEET

Provider: RODMAN & RENSHAW, CO.

Analyst: KING M

Price: 75.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 552

07/26/2012

Daily Note

Pages: 17

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 50.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 553

07/26/2012

Company Report

Pages: 8

2Q12 Results; Eylea Wows Again; Upgrade to Buy

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 554

07/20/2012

Daily Note

Pages: 10

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 555

07/20/2012

Daily Note

Pages: 4

ODYSSEY Begins, Extensive PCSK9 Program Launched by Sanofi

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 556

07/20/2012

Company Report

Pages: 7

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 557

06/22/2012

Company Report

Pages: 8

Price: 24.95

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 558

06/14/2012

Daily Note

Pages: 10

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 25.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 559

06/13/2012

Company Report

Pages: 4

Fovista and Lucentis Positive Wet AMD Data "Appear" to Threaten Eylea

Provider: Roth Capital Partners, Inc.

Analyst: PANTGINIS J

Price: 10.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 560

05/09/2012

Daily Note

Pages: 25

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 75.00

Research Provided by a Third Party